In summary, this study identified the anti-TCP1 antibody as a potential biomarker for SLE, showing higher expression rates than the known anti-RPLP0, RPLP1, and RPLP2 antibodies. This evidence concerns the gene RPLP2 and systemic lupus erythematosus.